Blood:HIT抗原的动态细胞间交换可调控肝素诱导的血小板减少症

2018-06-19 MedSci MedSci原创

肝素诱导型血小板减少症(HIT)是血小板因子4(PF4)/肝素复合物抗体引发的一种血栓形成前疾病。血小板释放的PF4与造血细胞和血管细胞表面的粘多糖结合,上述两种细胞的成分不同,对PF4的亲和力也不同。PF4与单核细胞结合的亲和力强于与血小板结合的亲和力;耗竭单核细胞可恶化HIT小鼠模型的血小板减少症。Jing Dai等人发现PF4在血小板上的表达和血小板减少症的进展均受PF4在造血细胞和内皮细胞

肝素诱导型血小板减少症(HIT)是血小板因子4(PF4)/肝素复合物抗体引发的一种血栓形成前疾病。血小板释放的PF4与造血细胞和血管细胞表面的粘多糖结合,上述两种细胞的成分不同,对PF4的亲和力也不同。PF4与单核细胞结合的亲和力强于与血小板结合的亲和力;耗竭单核细胞可恶化HIT小鼠模型的血小板减少症。

Jing Dai等人发现PF4在血小板上的表达和血小板减少症的进展均受PF4在造血细胞和内皮细胞表面的分布调控。在体外,PF4在全血中与血小板结合与白细胞计数呈负相关,可能是因为PF4与单核细胞结合的亲和力更强。

在小鼠中,单核细胞耗竭可增加2-3倍的PF4与血小板结合。在小鼠上诱导HIT可引起HIT抗体与单核细胞结合量一过性增加80多倍,迅速导致一过性单核细胞减少症,而与血小板的结合了仅增加3.5倍。单核细胞计数先于血小板计数恢复正常。将血液暴露于内皮细胞也可消耗血小板表面的PF4。

本研究结果表明造血细胞和血管细胞表面结合的PF4之间存在动态交换,可限制HIT模型的血小板减少症,但会促进血栓前期进展。

原始出处:

Jing Dai, et al.Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia.Blood  2018  :blood-2018-02-830737;  doi: https://doi.org/10.1182/blood-2018-02-830737

本文系williamhill asia 医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894501, encodeId=41431894501b6, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Aug 07 16:09:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302790, encodeId=fcf31302e90fb, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540608, encodeId=e25815406084d, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623295, encodeId=07441623295e7, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=)]
    2018-08-07 yuandd
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894501, encodeId=41431894501b6, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Aug 07 16:09:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302790, encodeId=fcf31302e90fb, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540608, encodeId=e25815406084d, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623295, encodeId=07441623295e7, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894501, encodeId=41431894501b6, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Aug 07 16:09:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302790, encodeId=fcf31302e90fb, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540608, encodeId=e25815406084d, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623295, encodeId=07441623295e7, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1894501, encodeId=41431894501b6, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Tue Aug 07 16:09:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302790, encodeId=fcf31302e90fb, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540608, encodeId=e25815406084d, content=<a href='/topic/show?id=4aa88133972' target=_blank style='color:#2F92EE;'>#肝素诱导的血小板减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81339, encryptionId=4aa88133972, topicName=肝素诱导的血小板减少症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43b613270021, createdName=kkunny, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623295, encodeId=07441623295e7, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Thu Jun 21 07:09:00 CST 2018, time=2018-06-21, status=1, ipAttribution=)]